Centene Valuation
Is C1NC34 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of C1NC34 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: C1NC34 (R$341.36) is trading below our estimate of fair value (R$1222.12)
Significantly Below Fair Value: C1NC34 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for C1NC34?
Key metric: As C1NC34 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is C1NC34's PE Ratio? | |
|---|---|
| PE Ratio | 9.5x |
| Earnings | US$3.07b |
| Market Cap | US$29.01b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.2x |
| Enterprise Value/EBITDA | 5.4x |
| PEG Ratio | 1.9x |
Price to Earnings Ratio vs Peers
How does C1NC34's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 17x | ||
ODPV3 Odontoprev | 10.5x | 3.1% | R$5.6b |
RDOR3 Rede D'Or São Luiz | 18.3x | 17.8% | R$66.1b |
HUM Humana | 24.4x | 11.6% | US$34.1b |
MOH Molina Healthcare | 14.7x | 14.8% | US$17.5b |
C1NC34 Centene | 9.5x | 4.9% | R$29.0b |
Price-To-Earnings vs Peers: C1NC34 is good value based on its Price-To-Earnings Ratio (9.5x) compared to the peer average (17x).
Price to Earnings Ratio vs Industry
How does C1NC34's PE Ratio compare vs other companies in the Global Healthcare Industry?
| 13 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 13 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: C1NC34 is good value based on its Price-To-Earnings Ratio (9.5x) compared to the Global Healthcare industry average (20.7x).
Price to Earnings Ratio vs Fair Ratio
What is C1NC34's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 9.5x |
| Fair PE Ratio | 11.8x |
Price-To-Earnings vs Fair Ratio: C1NC34 is good value based on its Price-To-Earnings Ratio (9.5x) compared to the estimated Fair Price-To-Earnings Ratio (11.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Rede D'Or São Luiz
R$65.9b
Operates a network of hospitals in Brazil.
RDOR3
R$29.50
7D
1.5%
1Y
13.9%
Baumer
R$113.8m
Develops solutions for health industry in Brazil.
BALM3
R$13.00
7D
-3.0%
1Y
n/a
Universal Health Services
US$13.4b
Through its subsidiaries, owns and operates acute care hospitals, and outpatient and behavioral health care facilities.
U1HS34
US$292.61
7D
1.8%
1Y
n/a